Biomarker-Driven Lung Cancer

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with non–small cell lung cancer.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

Sevabertinib demonstrated high and durable objective response rates in pretreated and treatment-naive HER2-mutant NSCLC, with a manageable safety profile.

Adagrasib plus pembrolizumab improved efficacy in KRAS G12C-mutant NSCLC, according to data from the KRYSTAL-7 trial.

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung cancer.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive non–small cell lung cancer.

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for repotrectinib in non–small cell lung cancer.

Pending phase 3 trial results, a biologics license application will be submitted for the KRAS-targeting cancer vaccine ELI-002.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.

BBO-8520, an investigational oral agent, has been granted fast track designation from the FDA in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

The FDA has granted ensartinib approval for adult patients with ALK-positive non–small cell lung cancer.

During a Case-Based Roundtable® event, Chul Kim, MD, moderated a discussion on current use of ALK TKIs in lung cancer in the second article of a 2-part series.

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation.

During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article of a 2-part series.

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.

The study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy in advanced first-line non–small cell lung cancer.